Future Research Priorities in Smoldering Multiple Myeloma

In this closing segment, Dr. Sagar Lonial asks the panel to reflect on the most important unanswered questions that remain in smoldering multiple myeloma research and what evidence is still needed before early treatment strategies are more broadly adopted. Dr. Vincent Rajkumar notes that improving the ability to identify which patients are most likely to progress remains a key priority. Refining risk stratification tools and integrating emerging biomarkers may help clinicians better distinguish patients who could benefit from early therapy from those who may be safely monitored. Dr. Saad Usmani adds that longer follow up from ongoing clinical trials will be important to better understand the long term benefits and potential risks of early intervention. As the discussion concludes, the panel emphasizes that careful patient selection, continued research, and thoughtful interpretation of emerging data will be essential in shaping the future management of smoldering multiple myeloma.